Isconova Reaches Milestone in Influenza Vaccine Collaboration
Isconova announced that the PANFLUVAC consortium consisting of eight European research partners has completed the first stage of their phase I clinical trial in healthy volunteers, using a pandemic A/H5N1 virosomal vaccine formulated with Isconova’s Matrix-M™ adjuvant.
The clinical trial was conducted in 60 subjects at the University of Bergen, Norway to assess the safety, tolerability and immunogenicity of the pandemic H5N1 influenza vaccine. The primary safety and tolerability endpoints of the Phase I study are the lack of local and systemic adverse events and tolerability of the parenterally administered vaccine.
The virosomal H5N1 influenza vaccine formulated with the Matrix-M™ adjuvant was well-tolerated and no serious adverse events were reported. The evaluation of the vaccine immunogenicity is ongoing.
“Isconova is delighted that the PANFLUVAC consortium has entered into a healthy volunteer Phase I study with the pandemic A/H5N1 virosomal vaccine formulated with Isconova’s Matrix-M™ adjuvant. This is an important milestone for Isconova and we look forward to continuing our collaboration with the PANFLUVAC consortium and to seeing the outcome of this study in 2010”, commented Dr Bengt Falk, Chief Executive Officer of Isconova.
Other news from the department research and development
